Stockwinners Market Radar for November 25, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EST Citius Pharmaceuticals trading halted, news pending

19:50 EST Cemtrex trading halted, news pending

19:33 EST Trump says will impose 25% tariff on all products from Mexico, Canada - U.S. President-elect Donald Trump said in posts on Truth Social, "As everyone is aware, thousands of people are pouring through Mexico and Canada, bringing Crime and Drugs at levels never seen before. Right now a Caravan coming from Mexico, composed of thousands of people, seems to be unstoppable in its quest to come through our currently Open Border. On January 20th, as one of my many first Executive Orders, I will sign all necessary documents to charge Mexico and Canada a 25% Tariff on ALL products coming into the United States, and its ridiculous Open Borders. This Tariff will remain in effect until such time as Drugs, in particular Fentanyl, and all Illegal Aliens stop this Invasion of our Country! Both Mexico and Canada have the absolute right and power to easily solve this long simmering problem. We hereby demand that they use this power, and until such time that they do, it is time for them to pay a very big price! I have had many talks with China about the massive amounts of drugs, in particular Fentanyl, being sent into the United States - But to no avail. Representatives of China told me that they would institute their maximum penalty, that of death, for any drug dealers caught doing this but, unfortunately, they never followed through, and drugs are pouring into our Country, mostly through Mexico, at levels never seen before. Until such time as they stop, we will be charging China an additional 10% Tariff, above any additional Tariffs, on all of their many products coming into the United States of America. Thank you for your attention to this matter." Reference Link

18:14 EST P10: HPS Investment Partners, Enhanced Capital launch partnership - P10 announced the launch of a new partnership between funds managed by HPS Investment Partners and Enhanced Capital, a P10 affiliated manager, that will provide structured capital solutions for renewable energy and battery energy storage projects throughout the United States. The investments made by the partnership will be designed to provide capital to energy transition projects while simplifying the monetization of renewable energy tax credits without the need for complex tax equity structures.

18:05 EST Sleep Number 'surprised' by Stadium demand, 'confident' in CEO succession plan - Sleep Number Corporation issued the following statement in response to the public letter to shareholders from Stadium Capital Management, LLC: "The Board of Directors (the "Board") and leadership team of Sleep Number welcome shareholder input and suggestions. To that end, we have engaged extensively with Stadium and last November added two directors recommended by Stadium to the Board. Over the last 12 months, members of our Board and leadership team have spoken with Stadium on more than a dozen occasions, and Stadium participated in four meetings with the Board's Capital Allocation and Value Enhancement Committee. On October 30, 2024, Sleep Number announced a set of comprehensive and thoughtfully considered changes to the Company's leadership and governance, including a CEO transition and Board refreshment and declassification. These reforms, which were carefully planned, were consistent with nearly all the suggestions we had received from Stadium over the past year. As we expressed to Stadium at the time, executing an effective CEO succession process and identifying and recruiting the next CEO is the highest priority for the Board. The Board has prepared extensively for this process and is confident in its approach to CEO succession... Given our robust approach, we were surprised when Stadium made the highly unusual demand that it be granted direct participation in the CEO succession process. There is no predicate, in our view, for changing the Board's best-in-class CEO search process. As noted, our process has been underway for many months and has already identified highly qualified candidates. Resetting the process to accommodate a single shareholder's desire for direct participation on the Committee may discourage participation by CEO candidates and would likely delay the appointment of a new CEO. That said, the Committee and Sleep Number's Board remain interested in Stadium's perspectives and input. To that end, three independent directors met with Stadium to describe our process and listen to Stadium's views on the qualities it desires in a new CEO. Further, the Committee invited Stadium to present its views and ask questions to the entire Committee and Korn Ferry last week. Stadium abruptly withdrew its participation less than 24 hours before the meeting was scheduled to take place. The Board invited the Company's top 20 shareholders to share their views on CEO succession. The Board appreciates the contributions of those shareholders that have shared their views already and welcomes all stakeholders to provide their perspectives. Despite Stadium's refusal to present its views to the Committee and Korn Ferry, Sleep Number's Board and the Committee remain open to Stadium's input. The Board reiterates that its highest priority is identifying and recruiting the optimal candidate."

17:53 EST Novonix trading halted, news pending

17:33 EST Concentra announces completion of spin-off from Select Medical - Concentra (CON) announced that Select Medical Holdings (SEM) has completed its previously announced distribution of 104,093,503 shares of Concentra's common stock owned by Select Medical Corporation, a wholly owned subsidiary of Select Medical, representing approximately 81.7% of the outstanding shares of Concentra's common stock. After the completion of the Distribution, Select Medical no longer owns any shares of Concentra's common stock. The Distribution was made to Select Medical's stockholders as of the close of business on November 18. The Distribution took place in the form of a pro rata common stock distribution to each of Select Medical's stockholders on the Record Date. Based on the shares of Select Medical's common stock outstanding on the Record Date, Select Medical's stockholders received 0.806971 shares of Concentra's common stock for every share of Select Medical's common stock held as of the Record Date. No fractional shares of Concentra's common stock were distributed. Instead, Select Medical's stockholders will receive cash in lieu of any fraction of a share of Concentra's common stock that they otherwise would have received.

17:29 EST Amazon Web Services awarded $158.25M Army contract - Amazon Web Services was awarded a $158.25M firm-fixed-price contract for cloud computer and storage services. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of September 21, 2028. U.S. Army Contracting Command is the contracting activity.

17:27 EST BAE Systems awarded $212.12M Navy contract action - BAE Systems was awarded a $212.12M firm-fixed-price contract action for maintenance, modernization and repair of USS Green Bay, or LPD 20, for fiscal 2025 docking selected restricted availability. The scope of this acquisition includes all labor, supervision, equipment, production, testing, facilities, and quality assurance necessary to prepare for and accomplish the Chief of Naval Operations availability for critical modernization, maintenance, and repair programs. This contract includes options, which, if exercised, would bring its cumulative value to $238,81M. Work will be performed in San Diego, California, and is expected to be completed by October 2026. FY25 other procurement, Navy funds in the amount of $180.29M and FY25 operation and maintenance, Navy funds in the amount of $31.82M will be obligated at the time of award, of which $31.82M will expire at the end of the current fiscal year. This contract was competitively solicited using full and open competition via the SAM website, with one offer received. The Naval Sea Systems Command is the contracting activity.

17:11 EST Guardant says jury unanimously found in favor of company in Natera suit - Guardant Health (GH) announced that a jury in the U.S. District Court for the Northern District of California unanimously found in favor of Guardant Health on all of its claims from its May 2021 lawsuit against Natera, Inc. (NTRA) for false advertising and unfair competition. The jury awarded $292.5M to Guardant Health, including $175.5M in punitive damages, representing one of the largest false advertising verdicts in history. The jury unanimously rejected all of Natera's counterclaims. The jury found that Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal - Guardant Health's tissue-free minimal residual disease test for early-stage colorectal cancer - in favor of Signatera, Natera's competing product. "Today's unanimous verdict holding Natera responsible for engaging in illegal and anticompetitive conduct represents a major victory for CRC patients who could benefit from our groundbreaking Reveal test, and we thank the jury and the Court for their careful consideration of our claims," said John Saia, Chief Legal Officer at Guardant Health. "Every company in the cancer diagnostics space has a duty to prioritize patients above all else. In keeping with our mission to help cancer patients lead longer and healthier lives, we strongly believe it is vital that clinicians receive accurate, complete, and truthful information to inform their decisions about potentially life-saving patient treatments."

16:43 EST Woodward jumps almost 14% after Q4 report and guidance surpass estimates - Shares of aerospace and industrial firm Woodward are up over $24 per share or approximately 14% to $202.05 on Monday in after hours trading, after reporting fourth quarter EPS and revenue ahead of analyst estimates. "Woodward's fiscal 2025 guidance includes a continued strong demand environment and improving operational performance throughout the year. The Aerospace segment guidance includes increasing revenue and margin expansion driven by continued strength in commercial markets and increased defense activity," the company said in its release.

16:33 EST Kohl's CEO Kingsbury to step down effective January 15, 2025 - Kohl's Corporation announced that Chief Executive Officer Tom Kingsbury plans to step down as CEO, effective January 15, 2025. He will stay on in an advisory role to the new CEO and retain his position on Kohl's Board of Directors through his retirement in May 2025, after which the size of the board will be reduced by one. The Board has appointed retail veteran Ashley Buchanan as CEO, effective January 15. Buchanan has been CEO of Michaels Companies since 2020 and, prior to that, has held a variety of senior executive roles at Walmart and Sam's Club during his 13 years at the company. Board Chair Michael Bender stated, "The Board is very grateful for Tom's leadership and ongoing service to Kohl's. Tom joined our Board in 2021. He then stepped up as interim CEO in 2022 and agreed to take the permanent position as CEO through May 2025. Under his leadership, the company is undergoing a transformation to elevate its product portfolio, enhance the store experience and improve its long-term financial health and profitability. On behalf of all Kohl's associates, we thank Tom for his leadership, for his role working with the Board on our CEO search, and for supporting Ashley through this transition."

16:32 EST Dana announces plans to sell Off-Highway business - Dana announced it has engaged financial advisors Goldman Sachs & Co. and Morgan Stanley & Co. to sell its Off-Highway business, which the Board believes will unlock substantial value for shareholders. The Off-Highway business provides drive and motion systems for heavy-duty vehicles in markets such as agriculture, materials handling, mining, construction and forestry. A sale will position Dana with a streamlined go-to-market approach focused on serving its light and commercial vehicle customers, with traditional and electrified products that are largely shared across the remaining portfolio. Proceeds from a potential sale will enable Dana to strengthen its balance sheet through substantially reduced leverage, and to return capital to shareholders. While the company and its advisors believe there is strong interest in the Off-Highway business, there can be no assurance that the sale process for Off-Highway will result in a transaction. There is no timeframe for the conclusion of the process, and the company does not intend to comment further regarding this matter unless and until further disclosure is determined to be appropriate.

16:31 EST NJR Clean Energy Ventures sells residential solar portfolio to Spruce Power - NJR Clean Energy Ventures, a clean energy subsidiary of New Jersey Resources (NJR), announced the sale of its 91 megawatt residential solar portfolio, to Spruce Power Holding Corporation (SPRU) for a total of $132.5M. NJR expects to record a gain on sale in fiscal 2025, and will use the proceeds to pay down corporate debt and for general working capital purposes. "Renewable energy investments are an integral part of our business and will continue to be a key driver of NJR's long-term growth strategy," said Steve Westhoven, President and CEO of New Jersey Resources. "Following this transaction, Clean Energy Ventures will have a sharpened focus on the strong opportunities for growth within its commercial solar portfolio, driven by a nearly 1 gigawatt (GW) pipeline of diverse investment options."

16:17 EST Alector announces AL002 trial misses endpoint, reduces workforce by 17% - Alector announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease, or AD. Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes, and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002.Based upon the results, Alector is stopping the long-term extension study. Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in frontotemporal dementia with a progranulin gene mutation is expected in late 2025 or early 2026. PROGRESS-AD, a global Phase 2 clinical trial evaluating AL101/GSK4527226 in early AD, has reached more than one-third of its target enrollment of 282 participants. Alector is also advancing its preclinical candidates aimed at a broad and diverse range of protein and enzyme targets. In addition to advancing its pipeline, the company is continuing to develop its blood-brain barrier technology platform, Alector Brain Carrier, or ABC. To align resources with these strategic priorities, Alector is reducing its workforce by approximately 17%. As of September 30, Alector has $457.2M in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide guidance for 2025 during its fourth-quarter and full-year earnings conference call.

16:15 EST Zoom Video increases share repurchase authorization by $1.2B - Zoom's board of directors authorized the repurchase of an additional $1.2B of Zoom's outstanding Class A common stock. This authorization is in addition to the amount remaining under the prior authorization for the share repurchase program, for a total of approximately $2B remaining to be repurchased.

16:11 EST SITE Centers announces tax estimate for Curbline Properties distribution - SITE Centers Corp. (SITC) provided additional information related to the spin-off and distribution of Curbline Properties Corp. (CURB). On October 1, 2024, each shareholder of SITE Centers received two common shares of Curbline Properties in a taxable spin. The fair market value of the CURB shares received by SITE Centers shareholders for federal income tax purposes has been determined by SITE Centers to be $22.29 per CURB share. Based upon preliminary taxable net income analysis to date, the company estimates that approximately 21% of the CURB distribution constitutes a taxable capital gain and approximately 79% constitutes a return of capital. Full year 2024 operating results for SITE Centers could result in a change to the character of the CURB distribution. The final determination of the tax treatment of total 2024 distributions will be reported to SITE Centers shareholders on Form 1099-DIV, which will be issued in January 2025.

16:06 EST Zimmer Biomet receives FDA approval for Oxford Cementless Partial Knee - Zimmer Biomet Holdings announced U.S. FDA Premarket Approval Application Supplement approval for the Oxford Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption study and non-clinical testing for cementless partial knee replacement, The Oxford Cementless Partial Knee allows surgeons to perform a PKR with improved fixation,2 better long-term implant survival rate2,3 and improved efficiency in the operating room compared to the Oxford Cemented Partial Knee procedure. Following more than 20 years of clinical experience and over 300,000 procedures across Canada, Europe, Middle East, Africa, and Asia, the Oxford Cementless Partial Knee is now the only FDA-approved cementless partial knee implant in the U.S.

16:03 EST Barinthus CSO Nadege Pelletier to depart, Geoffrey Lynn to succeed - Barinthus Biotherapeutics announced the promotion of Geoffrey Lynn to chief scientific officer, or CSO, effective as of December 1. Lynn succeeds Nadege Pelletier, who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio's CSO since early 2023.

16:02 EST Flux Power receives non-compliance letter from Nasdaq - Flux Power Holdings announced that on November 20, 2024, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 and its Annual Report on Form 10-K for fiscal year ended June 30, 2024, with the Securities and Exchange Commission. This notification has no immediate effect on the listing of the Company's common stock on the Nasdaq. Under the Nasdaq rules, the Company has until December 16, 2024, to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If Nasdaq accepts the Company's plan, then Nasdaq may grant the Company up to 180 days from the prescribed due date for the Form 10-K to regain compliance, or April 14, 2025. If Nasdaq does not accept the Company's plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel.

15:43 EST Musk says California plan that would exclude Tesla from EV credits 'insane' - Replying to a Bloomberg report that said California Governor Gavin Newsom announced that if the incoming Trump Administration eliminates a federal ZEV tax credit, he will propose creating a new version of the state's Clean Vehicle Rebate Program, which would exclude popular Tesla models from eligibility, Tesla CEO Elon Musk stated on X: "Even though Tesla is the only company who manufactures their EVs in California! This is insane." Reference Link

13:36 EST Formula One reaches agreement with GM for 11th team in 2026 - Liberty Formula One (FWONA) announced that it has reached an agreement in principle with General Motors (GM) to support bringing GM/Cadillac as the 11th team to the Formula 1 grid in 2026. "Formula 1 has maintained a dialogue with General Motors, and its partners at TWG Global, regarding the viability of an entry following the commercial assessment and decision made by Formula 1 in January 2024.Over the course of this year, they have achieved operational milestones and made clear their commitment to brand the eleventh team GM/Cadillac, and that GM will enter as an engine supplier at a later time. Formula 1 is therefore pleased to move forward with this application process and will provide further updates in due course," the company said in a statement. Reference Link

12:39 EST Hims & Hers jumps after Trump nominates Dr. Marty Makary for FDA - Shares of Hims & Hers are moving higher after President-elect Donald Trump nominated Dr. Marty Makary, a pancreatic surgeon at Johns Hopkins University, as commissioner of the Food and Drug Administration. Makary is also Chief Medical Officer at startup startup Sesame, which prescribes compounded GLP-1 weight loss drugs through the mail. Hims & Hers also sells compounded weight loss drugs. The stock in midday trading is up 18%, or $4.60, to $29.93.

12:01 EST Archer Aviation rises 28.0% - Archer Aviation is up 28.0%, or $1.69 to $7.73.

12:01 EST Vertical Aerospace rises 38.6% - Vertical Aerospace is up 38.6%, or $1.85 to $6.64.

12:00 EST Oklo falls -8.3% - Oklo is down -8.3%, or -$2.10 to $23.10.

11:01 EST Schneider National announces plans to acquire Cowan Systems for $390M in cash - Schneider National announced that the company, through certain wholly owned subsidiaries, has entered into a definitive agreement to acquire Cowan Systems, LLC and affiliated entities, for a cash purchase price of approximately $390M, subject to certain adjustments. The sale includes separate agreements to purchase certain real estate assets relating to Cowan Systems' business for approximately $31M in cash. "This acquisition aligns with Schneider's long-term vision to have customer-centric Dedicated solutions as the cornerstone of its Truckload segment. By complementing our organic Dedicated growth success with transactions like this, we are broadening our presence to provide greater value to our customers and stakeholders," said Schneider President and CEO Mark Rourke.

10:53 EST Tecogen receives orders for seven DTX chillers - Tecogen announced orders for seven 400-ton DTX chillers for the iconic Las Vegas Convention Center. These chillers are part of a project to modernize the convention center's Central Cooling Plant with newer, more efficient chillers, pumps, and other equipment.

10:44 EST Exicure Inc trading halted, volatility trading pause

10:32 EST EzFill signs agreement for purchase of Yoshi Mobility's fuel division - EzFill Holdings has signed a definitive agreement to acquire the fueling division of Yoshi, Inc. with the aim of expanding its U.S operations and presence. Under the terms of the agreement, EzFill will acquire Yoshi Mobility's existing mobile fuel service assets and allows EzFill to begin operations in four new states: California, Tennessee, Texas, and Michigan. EzFill will integrate Yoshi's assets, operations and customers into its growing infrastructure. With this acquisition, EzFill plans to not only strengthen the company's footprint in its existing markets but also take advantage of EzFill's national customers and begin offering services to them in those markets. EzFill will immediately add diesel fueling to the services currently offered by Yoshi in those markets which the Company believes will immediately increase revenues in those areas. Additionally, EzFill hopes to initiate an aggressive national expansion plan, positioning itself as a leading player in the on-demand fueling sector. Based in Nashville, Tennessee, Yoshi Mobility is a major mobility services provider backed by strategic investors such as General Motors Ventures, ExxonMobil, and Bridgestone Americas. These investments have played a pivotal role in establishing Yoshi Mobility as a trailblazer in the mobile fueling industry. As part of the Agreement Yoshi will become shareholders in EzFill. The definitive agreement contains customary closing conditions and is expected to close by December 2, 2024.

10:11 EST Arrow Electronics sings new agreement with Broadcom for VMware solutions - Arrow Electronics (ARW) signed a new agreement with Broadcom (AVGO) for the distribution of VMware solutions in the U.S. and Canada. Under the new agreement, Arrow will deliver VMware private cloud infrastructure solutions through its ArrowSphere platform, including VMware Cloud Foundation, VMware vSphere Foundation, VMware vSAN and VMware vSphere Standard. Channel partners can benefit from immediate access to Arrow's personalized assistance, training programs, and certified resources as part of its high-quality support services that span the commercial IT lifecycle.

10:07 EST VEON announces shares now trade exclusively on Nasdaq - VEON announces the consolidation of its share trading on the Nasdaq Capital Market in New York. Effective from today, VEON's common shares are no longer listed or traded on Euronext Amsterdam, with all public trading of VEON's equity securities now concentrated on Nasdaq. This strategic move is aimed at enhancing trading liquidity and simplifying reporting requirements for the company. VEON has also previously announced the decision to move its Group headquarters to Dubai, in closer proximity to the Company's Central and South Asian markets and increasing the visibility of VEON for Gulf investors. When the move is completed, VEON will be the largest Nasdaq-listed company with a Group headquarters in Dubai.

10:02 EST PPG completes sale of silicas products business to QEMETICA - PPG has completed the sale of its silicas products business for approximately $310M in pre-tax proceeds to QEMETICA a Warsaw, Poland-based, privately held manufacturer of soda ash, silicates and other specialty chemicals. PPG's silicas products business manufactures and supplies precipitated silica products to major companies around the world as performance-enhancing additives. In 2023, the silica products business represented between 1-2% of PPG's total net sales. The transaction includes PPG's precipitated silicas manufacturing facilities in Lake Charles, Louisiana, and Delfzijl, The Netherlands. In addition, QEMETICA will lease silicas manufacturing and research and development operations at PPG sites in Barberton, Ohio and Monroeville, Pennsylvania, respectively. The silicas products business is led by about 400 employees. The transaction is the result of PPG's evaluation of strategic alternatives for the business, which was first announced on January 9, 2024. Morgan Stanley & Co. LLC acted as PPG's financial advisor and Hogan Lovells served as its legal advisor.

10:00 EST Bath & Body Works rises 20.8% - Bath & Body Works is up 20.8%, or $6.40 to $37.11.

10:00 EST D-Wave Quantum rises 24.7% - D-Wave Quantum is up 24.7%, or 72c to $3.65.

10:00 EST Global Blue falls -9.7% - Global Blue is down -9.7%, or -58c to $5.38.

09:58 EST Quantum Corp trading resumes

09:53 EST S&W Seed trading resumes

09:48 EST D-Wave Quantum rises 12.3% - D-Wave Quantum is up 12.3%, or 36c to $3.29.

09:47 EST ZIM Integrated falls -6.9% - ZIM Integrated is down -6.9%, or -$1.63 to $22.15.

09:47 EST Global Blue falls -10.6% - Global Blue is down -10.6%, or -63c to $5.33.

09:33 EST Kodak trading resumes

09:32 EST Uxin Ltd trading halted, volatility trading pause

09:17 EST NexPoint Hospitality Trust to be acquired by NexPoint Diversified Real Estate - NexPoint Hospitality Trust and NexPoint Diversified Real Estate Trust announced the execution of a definitive agreement on November 22, pursuant to which the REIT will be dissolved and its subsidiary entities merged with and into entities owned or controlled, directly or indirectly, by NXDT. Pursuant to the Transaction, each REIT unitholder will receive, for each trust unit of the REIT, either 36c cash per Unit or common shares of NXDT equal to the quotient of 36c divided by the volume weighted average price of the NXDT Common Shares quoted on the New York Stock Exchange for the ten trading days prior to closing of the Transaction. Subject to the satisfaction of all conditions precedent, the Transaction is expected to be completed in the first quarter of 2025. Upon closing of the Transaction, the REIT's Units will be delisted from the TSX Venture Exchange. Raymond James Limited has entered into a voting and support agreement pursuant to which it has agreed to support and vote the Units it owns or over which it exercises control or direction over, including on behalf of accounts over which it has discretionary authority, in favour of the Transaction.

09:17 EST Merit Medical's WRAPSODY WAVE trial 'exceeds performance goals' for AVG patients - Merit Medical Systems announced six-month findings from the single-arm AVG cohort of its WRAPSODY Arteriovenous Access Efficacy pivotal trial. The data were presented at the 51st annual VEITHsymposium during the Novel Technologies in Hemodialysis Access session. An AVG is a synthetic tube that is used for long-term access to blood vessels for patients undergoing hemodialysis. However, over time, the graft may become narrow or blocked, resulting in potentially life-threatening consequences. Merit's WRAPSODY Cell-Impermeable Endoprosthesis is designed to restore and extend vessel access in hemodialysis patients, which is critical for patient survival. The WAVE trial was designed to evaluate the efficacy and safety of the WRAPSODY device. The AVG arm of the WAVE trial enrolled 112 patients across 43 international sites. All enrolled patients were treated with the WRAPSODY device. Based on survival analysis through six months, target lesion and access circuit primary patency for AVG patients in the WAVE trial were 82% and 68.8%, respectively. Primary efficacy and safety endpoints were assessed by comparing actual rates for the WRAPSODY device to performance goals for covered stents. Efficacy of the WRAPSODY device was 81.4%, which is 21.4 percentage points higher than the PG of 60%. The proportion of AVG patients who were free from an adverse event was higher than the safety PG.

09:13 EST Elastic collaborates with Amazon's AWS to leverage generative AI capabilities - Elastic (ESTC) it is strengthening its relationship with Amazon Web Services AWS (AMZN) by leveraging the latest generative artificial intelligence (AI) services from AWS. As part of this collaboration, Elastic is offering large language model LLM observability support for Amazon Bedrock in Elastic Observability. Amazon Bedrock is a fully managed service that offers a choice of high-performing foundation models FMs from leading AI companies via a single API, along with a broad set of capabilities organizations need to build generative AI applications with security, privacy, and responsible AI. The new integration offers Site Reliability Engineers SREs detailed insights into their Amazon Bedrock LLMs performance and usage. SREs can now leverage Elastic Observability to monitor invocations, errors, and latency metrics. This allows them to more proactively prevent incidents and identify root causes, ensuring optimal performance for their Amazon Bedrock-powered generative AI applications. Additionally, Elastic AI Assistant, which utilizes Amazon Bedrock, helps SREs accurately analyze data, generate visualizations, and provides actionable recommendations for issue resolution.

09:11 EST CNS Pharmaceuticals presents update from ongoing study of berubicin - CNS Pharmaceuticals announced the presentation of updated results from the on-going potentially pivotal study evaluating Berubicin, the Company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a randomized, controlled study vs. Lomustine, which has been considered to be a standard of care in this recurrent glioblastoma population. This was a poster presentation at the 29th Annual Meeting of the Society for Neuro-Oncology held November 21-24, 2024 in Houston, TX. The poster titled, "Update on a Potentially Pivotal Trial CNS-201: A Randomized, Controlled Trial of Berubicin Vs. Lomustine After First-Line Therapy for Glioblastoma Multiforme," was presented bySandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals. The data presented at the SNO Annual Meeting include comparative demographics, disposition of patients, MGMT promoter methylation status and safety, showing that the balance between the randomized arms has been maintained through enrollment of 239 patients into the study. Summary of Updated Results from the Potentially Pivotal Study: All patients enrolled show comparable demographics within each arm, including age, gender, race, BSA, and KPS. In addition, patients with unmethylated MGMT comprise approximately 40% in both arms, allowing for a reasonable comparison of efficacy irrespective of the methylation status. There is a slightly greater percentage of patients on the Berubicin arm compared to the Lomustine arm that have completed the study, but a greater percentage of patients on the Lomustine arm have withdrawn from the study, the most common reasons being patient preference and death. All grades of any reported adverse events and those of Grade 3-5 in severity occurring in more than 10% of patients are shown to be relatively similar in the Berubicin and Lomustine arms. A slightly greater percentage of patients with all grades or Grades 3-5 with anaemia, headache, and decrease in neutrophil counts were shown in patients receiving Berubicin, while a significantly greater percentage of patients with a decrease in platelet counts and thrombocytopenia occurred in patients receiving Lomustine. The primary endpoint of the study is Overall Survival, a rigorous endpoint the FDA has recognized as the basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. As previously announced in April 2024, the Company completed enrollment with 252 patients in this study evaluating Berubicin vs. Lomustine for the treatment of GBM. In December 2023, the Company announced the successful completion of its pre-planned interim futility analysis of efficacy and safety and received a recommendation from the independent Data Safety Monitoring Board to continue the study without modification. CNS Pharmaceuticals expects to report primary analysis data from its potentially pivotal study of Berubicin in the first half of 2025.

09:08 EST Kodak reviewing options with respect to KRIP, including possible termination - In a regulatory filing, Eastman Kodak (KODK) disclosed that on November 20, the Kodak Retirement Income Plan Trust, in its capacity as holder of assets for the benefit of the Kodak Retirement Income Plan, or "KRIP," entered into a Purchase and Sale Agreement with Mastercard Foundation (MA). Pursuant to the agreement, the Trust agreed to sell and the buyer agreed to purchase certain private equity ownership interests and other illiquid assets held by the Trust for the benefit of KRIP having an aggregate net asset value as of March 31 of $764.4M for a purchase price of $550.6M payable in cash at closing. "Subsequent to the entry into the Agreement, the Trust entered into or expects to enter into in the near term Purchase and Sale Agreements similar to the Agreement with four other investors pursuant to which the Trust agreed or will agree to sell and such investors agreed or will agree to purchase certain KRIP Illiquid Assets having an aggregate net asset value as of the Reference Date of $87.3M for a purchase price of $61.7M payable in cash at closing, except for $15.3M of cash proceeds which are payable on a deferred basis on December 31, 2025. The Sale Agreements were entered into as a result of the previously announced secondary sale process with respect to the KRIP Illiquid Assets being conducted by a third-party broker. Assuming the consummation of the transactions contemplated by the Sale Agreements, the Trust will continue to hold KRIP Illiquid Assets having a net asset value of $161.3M as of September 30, 2024. KRIP also owns interests in hedge funds having a net asset value of $917.2M as of September 30, 2024 which are not included in the KRIP Illiquid Assets. As previously reported, redemption notices have been given with respect to a substantial majority of Hedge Fund Assets and KRIP expects to receive proceeds from the redemption of those Hedge Fund Assets in accordance with the agreements governing the relevant Hedge Fund Assets. The Board of Directors of Eastman Kodak Company, the settlor of KRIP, is reviewing options with respect to KRIP, including the possible termination of KRIP, and has instructed the committee with authority to manage KRIP's assets to take actions appropriate to position KRIP for a potential termination. At this time, the Board has not yet made a formal determination to terminate KRIP. The following disclosure summarizes what Kodak expects and projects to occur in the event of a termination of KRIP assuming the transactions under the Sale Agreements are consummated as contemplated and the Board determines to terminate KRIP. A termination of KRIP would not impair the accrued benefits of any participant under KRIP; rather, the first step in the termination process would be the satisfaction of KRIP's liabilities to all participants in a manner complying with applicable laws. It is anticipated that KRIP's liabilities would be satisfied through a combination of lump sum distributions to active and terminated vested participants who elect a lump sum distribution and the purchase of an annuity from an insurance company with respect to existing KRIP annuity obligations for current retirees and beneficiaries and annuity obligations arising from the termination to active and terminated vested participants who do not elect to receive lump sum distributions. The cost to satisfy KRIP's liabilities will be affected by a variety of factors including interest rate fluctuations, the portion of active and terminated vested participants who elect lump-sum distributions, the premium payable to purchase the annuity, and other actuarial factors used to calculate the value of KRIP's ongoing annuity obligations," the filing noted.

09:05 EST Kodak Retirement Income Plan Trust to sell some assets to Mastercard Foundation - In a regulatory filing, Eastman Kodak disclosed that on November 20, the Kodak Retirement Income Plan Trust, in its capacity as holder of assets for the benefit of the Kodak Retirement Income Plan, or "KRIP," entered into a Purchase and Sale Agreement with Mastercard Foundation (MA). Pursuant to the agreement, the Trust agreed to sell and the buyer agreed to purchase certain private equity ownership interests and other illiquid assets held by the Trust for the benefit of KRIP having an aggregate net asset value as of March 31 of $764.4M for a purchase price of $550.6M payable in cash at closing. "The closing is scheduled to occur as of December 31, 2024, but a portion of the KRIP Illiquid Assets subject to the Agreement may be sold at one or more subsequent closings in accordance with the terms of the Agreement. The Agreement contains representations, warranties, covenants, conditions and other provisions customary for secondary sales of private equity investments," the filing stated. Reference Link

09:04 EST Gemini Bioproducts acquires selected FBS product rights from Bio-Techne - Gemini Bioproducts announced the acquisition of selected fetal bovine serum product rights and inventory from Bio-Techne. GeminiBio has a 39-year history of supporting FBS customers. With this agreement, GeminiBio builds on these capabilities, by securing the manufacturing and global sales rights for Bio-Techne's R&D Systems fetal bovine serum product brands, Optima, Premium Select, and Premium. Following Bio-Techne's decision to discontinue their FBS products, GeminiBio worked closely with the company to create a seamless transition plan, ensuring continuous access to these high-quality FBS products for existing customers. The effective date for the transition of these products to GeminiBio is December 3.

09:04 EST Philips, icometrix to deploy AI solution for reporting results of MRI scans - Royal Philips and icometrix have teamed up to deploy an AI-driven, end-to-end solution for acquiring, reading, and reporting the results of MRI brain scans to optimize diagnosis and treatment monitoring of neurological conditions including Alzheimer's and multiple sclerosis. Unveiled at RSNA 2024, icometrix's unique AI-powered quantitative reporting software is seamlessly integrated into Philips' latest BlueSeal MR scanners through Philips' new Smart Reading capability, providing consistent and more accurate diagnosis. The software will also be deployed on Philips' healthcare informatics platform - including Philips cloud-based AI Manager.

09:02 EST DoorDash announces partnership with InComm Payments - InComm Payments and DoorDash announced a partnership enabling consumers to browse, purchase and order delivery of gift cards for hundreds of merchants within the DoorDash app. The offering will launch on Friday, Nov. 29, with promotions beginning on Black Friday that offer limited-time discounts on select digital gift card orders made through the app or website* by eligible customers. In addition to physical gift card deliveries from local merchants, consumers can conveniently order physical gift cards from DashMart - a new type of fulfillment platform and store from DoorDash that offers businesses big and small a new channel to reach customers. InComm Payments manages the supply of popular gift cards to DashMart locations across the country, enabling Dashers to quickly pick up orders and deliver them to customers.

08:59 EST Nordic American Tankers announces results of annual meeting - Nordic American Tankers conducted its Annual General Meeting of Shareholders Thursday, November 21, 2024 in Monaco. The company said, "A quorum was present, and the following resolutions were approved and adopted at the Meeting: Election of Founder, Chairman & CEO Herbjorn Hansson to serve as Director & Chairman of the Board; Election of Alexander Hansson to serve as Director of the Board; Election of Jenny Chu to serve as Director of the Board; Approval of the appointment of KPMG as the Company's independent auditors. The board has the authority to replenish a vacant position, to ensure that the NAT Board always consists of four members. We are in a strong market and prospects are good."

08:56 EST LPL Financial: Happier Wealth joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Will Beck, Mike Macfarlane, Tyler Vongsawad and Sam Rosen have joined LPL Financial's broker-dealer, RIA and custodial platforms to launch a new independent practice, Happier Wealth. They reported having served approximately $250 million in advisory, brokerage and retirement plan assets and join LPL from Northwestern Mutual. Located in Pleasant Grove, Utah, the Happier Wealth team has more than 70 years of collective experience in financial services. Macfarlane mentored Beck and Vongsawad as college interns, and they have all remained close friends throughout their careers. As the three founding partners of Happier Wealth, the advisors are looking to build a collaborative environment where they can live out their mission of helping clients live happier, more fulfilled lives.

08:47 EST TuHURA Biosciences sees cash runway into 2H25 - In connection with the Company's recently completed merger with Kintara, a $31 million fully-funded financing was closed and is expected to fund planned operations late into the second half of 2025. Prior to the merger, the Company raised an additional $5 million to fund the Exclusivity and Right of First Offer Agreement with Kineta relating to KVA12123, its Phase 2 ready VISTA inhibiting antibody, which would be applied to the acquisition consideration if a definitive agreement is entered into with Kineta.

08:45 EST Volato launches 'new premium membership tier' Vaunt Cabin Plus - Volato Group announced that Vaunt,"the leading private aviation platform for accessing affordable private aviation experiences, launched its new premium membership tier, Vaunt Cabin Plus, and the rebranding of its existing membership as Vaunt Core. These significant milestones underscore Vaunt's commitment to redefining the private aviation experience for its members...Vaunt Core: Formerly known as the standard Vaunt membership, this tier offers access to light jets for up to four passengers, providing a cost-effective entry into private aviation.....The launch of Vaunt Cabin Plus represents a new chapter in our mission to democratize private aviation," said Nicholas Cooper, President of Vaunt. "These membership tiers deliver value to our members and are designed to support the growth of our recently announced Third Party Operator Program while increasing our flight inventory for members."

08:44 EST TuHURA Biosciences outlines development pathway for IFx-2.0 - TuHURA Biosciences provided a business update and outlined upcoming targeted milestones. "We have made significant progress toward accomplishing our 2024 corporate objectives, including reaching a Special Protocol Assessment agreement with the FDA by working with the Oncology Center of Excellence and FDA's Project Front Runner initiative for a novel Phase 3 trial design for IFx-2.0 under the FDA's accelerated approval pathway. This single registration directed trial, in addition to its primary endpoint of Overall Response Rate, it will also incorporate a key secondary endpoint of Progression Free Survival that, if achieved, can satisfy the requirement for a post-approval confirmatory trial, potentially converting accelerated approval to full approval," commented James Bianco, CEO. "We have also advanced our efforts toward the potential acquisition of KVA12123, a novel VISTA inhibiting antibody, with a non-binding letter of intent, which would bring to our pipeline a Phase 2 ready candidate with therapeutic synergies across our pipeline and technologies, all while becoming a NASDAQ-listed Company after having raised significant capital adequate to advance our current programs late into the second half of 2025." Innate Immune Response Agonists: TuHURA's IFx technology utilizes a proprietary plasmid DNA or messenger RNA which, when introduced into or targeted to a tumor, results in the expression of a highly immunogenic gram-positive, bacterial protein on the surface of the tumor cell, making the tumor look like a bacterium. Gram-positive bacterium has molecular patterns, or motifs, preserved over evolution which are recognized by receptors on our immune cells called toll like receptors. TLR 2 specifically recognizes the pattern of gram-positive bacterial proteins, like Emm55 leading to the activation of antigen presenting cells. Once activated, APCs digest the tumor cell and present non-self, tumor neoantigens to newly produced T and B cells, activating a tumor-specific adaptive immune response. Through its activation of tumor specific T cells, IFx-2.0 administration can potentially overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single, randomized, placebo-controlled Phase 3 accelerated approval trial of IFx-2.0 administered as an adjunctive therapy to Keytruda versus pembrolizumab plus placebo in first line treatment for checkpoint inhibitor-naive patients with advanced or metastatic MCC. The data from the Company's Phase 1b trial in patients with advanced or metastatic MCC who exhibited primary resistance to CPI was used to support a potential single registration directed trial. Consistent with the FDA's Project Front Runner Initiative, the FDA's OCE recommended investigating IFx-2.0 in the first line setting rather than in patients progressing on first line therapy. Project Front Runner is an FDA OCE initiative to encourage drug sponsors to consider when it may be appropriate to first develop and seek approval of new cancer drugs for advanced or metastatic disease, in an earlier clinical setting rather than the usual approach to develop and seek approval of a new drug for treatment of patients who have received numerous prior lines of therapies or have exhausted available treatment options. The FDA also encouraged the Company to consider designing the trial to include a key secondary endpoint shown to be of clinical benefit like PFS allowing this accelerated approval trial to potentially satisfy both the requirements for accelerated approval based on ORR, while satisfying the requirement for a post-approval confirmatory trial if the secondary PFS endpoint is achieved. The trial will be conducted under an SPA agreement with the FDA. Tumor Microenvironment Modulators: Leveraging its Delta receptor technology, TuHURA is developing bi-specific immune modulating ADCs or PDCs targeting MDSCs to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Potential Acquisition of Novel Anti-VISTA Checkpoint Inhibitor: As previously announced on July 8, 2024, TuHURA entered into an Exclusivity and Right of First Offer Agreement with Kineta for the potential acquisition of Kineta's KVA12123 VISTA inhibiting antibody. TuHURA has continued to engage in discussions and negotiations with Kineta and has entered into a non-binding letter of intent regarding a potential transaction in which TuHURA would acquire the rights to KVA12123 for a combination of cash and shares of TuHURA common stock via a merger transaction structure. KVA12123 has completed enrollment in its monotherapy arm, demonstrating safety at its highest dose level. Kineta anticipates completion of enrollment in the combination therapy arm where KVA12123 is administered with Merck's anti-PD1 therapy, KEYTRUDA. Initial results were reported earlier this year at the American Association of Cancer Research Annual Meeting 2024 and recently at the Society for Immunotherapy of Cancer meeting.

08:40 EST Perfect Moment teams with luxury fashion sales agency, CD Network - Perfect Moment has partnered with renowned luxury fashion sales agency, CD Network, to expand its wholesale distribution and bring greater brand awareness of Perfect Moment to North America. The agency will spearhead efforts in the U.S. and Canada, marking Perfect Moment's first sales agency engagement for these major markets. The partnership is expected to significantly increase brand visibility and relationships with key buyers and help set the stage for record sales of Perfect Moment's Fall/Winter 2025 collection. "We are excited to add Perfect Moment to our roster of influential brands as a global leader in fashion skiwear," stated CD Network founder and CEO, Christophe Desmaison. "Perfect Moment has infused fashion and vibrancy into the best technical gear, bringing style to the slopes. The brand's expanded offering with a city relevant range is sure to appeal to our designer store clientele." ...The integration phase has already begun, with new showrooms for New York City planned for December. Perfect Moment's skiwear offerings address the high-growth global luxury ski apparel market which is expected to reach $1.5B in 2024 and grow at a compound annual growth rate CAGR of 6.5% from 2024 to 2031, according to Global Research and Insights. The company also addresses an expanding market for luxury outerwear which is expected to total $15.9B in 2024, and forecasted to increase at a CAGR of 7% from 2024 to 2031, according to Absolute Market Research & Advisory.

08:39 EST Reborn Coffee announces readiness to mass produce 4th Wave Cold Brew line - Reborn Coffee announced its readiness to mass produce its newly designed 4th Wave Cold Brew line, with production scheduled to begin in early Q1 2025 in the United States, Malaysia, and Korea. This milestone follows Reborn's twice-earned recognition in prestigious U.S. cold brew contests, further strengthening its reputation for delivering premium cold brew beverages.

08:38 EST IGC Pharma announces additional interim data from IGC-AD1 trial - IGC Pharma announced additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1. The trial focuses on agitation in Alzheimer's as its primary outcome, with cognition assessed as an exploratory outcome. Interim data analysis reveals cognitive improvements in the active treatment group versus the placebo group, marking a meaningful step toward developing a therapy that may influence underlying disease progression. These findings align with previously announced preclinical data, which showed a reduction in amyloid plaque aggregation by approximately 20% and improved spatial memory by about 50% in Alzheimer's cell lines and mouse models, respectively. Cognitive decline in Alzheimer's disease reflects the deterioration of memory, attention, language, and reasoning due to underlying pathological changes, such as amyloid plaques and tau tangles. Interim results from the trial demonstrated that the active treatment group receiving IGC-AD1 twice daily for six weeks showed an average improvement of about 8% on the Mini-Mental State Examination, or MMSE, a validated clinical tool for assessing cognitive function. By contrast, the placebo group showed no improvement over the same period. These results and the preclinical data provide a robust foundation for future trials focusing on cognition as the primary endpoint and exploring IGC-AD1's disease-modifying potential. Agitation, a debilitating symptom affecting up to 76% of Alzheimer's patients, accelerates disease progression, increases caregiver burden, and drives hospitalization rates. As previously disclosed, interim results showed that IGC-AD1 significantly reduced agitation compared to placebo, with improvements observed as early as two weeks. Unlike the existing therapy, which often takes about 6-10 weeks to show results and carries a black box warning, IGC-AD1 offers rapid symptom relief with a favorable safety profile, making it a highly differentiated potential medication for managing agitation in Alzheimer's.

08:37 EST Tenaya Therapeutics doses first patient with TN-401 gene therapy - Tenaya Therapeutics announced that the first patient has been dosed with TN-401 gene therapy in the RIDGE-1 Phase 1b clinical trial at the University of California, San Francisco. Tenaya currently anticipates sharing initial data from the RIDGE-1 trial in 2025. TN-401 is being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy caused by mutations in the plakophilin-2 gene. The first dose of TN-401 being assessed in the RIDGE-1 clinical trial is 3E13 vg/kg, a dose that was associated with near maximal efficacy in preclinical studies. The first three patients will be dosed on a sequential basis. Once three patients have been dosed at the 3E13 vg/kg level, a panel of independent safety reviewers will advise on plans to dose escalate and/or expand enrollment of the initial cohort dosing in parallel.

08:36 EST Teladoc launches new AI-enabled capabilities for Virtual Sitter solution - Teladoc Health announced the launch of new AI-enabled capabilities to enhance its Virtual Sitter solution to improve patient safety, address workforce challenges, and enhance care delivery for hospitals and health systems. Every year, nearly 1 million hospitalized patients experience falls, with more than 30% resulting in lasting injuries. According to the CDC, falls result in approximately $50 billion of medical costs each year, and put additional strain on hospitals. Teladoc Health's Virtual Sitter solution helps address this critical issue. Leveraging AI, a single remote staff member can now monitor up to 25% more patients, helping to increase the capacity of healthcare inpatient teams. This latest innovation builds on Teladoc Health's broader suite of inpatient connected care solutions, which support virtual nursing, physician consults, interpretive services, and other hybrid care services that help reduce the administrative burden on bedside staff and improve both clinician and patient satisfaction. "For more than a decade, we've pioneered new ways for technology to support human interaction in patient care, helping hospitals and health systems transform care delivery and meet their most pressing challenges," said Andy Puterbaugh, Teladoc Health President of Hospitals and Health Systems. "New applications of AI are now accelerating our impact, supporting continuous improvement of our fully integrated suite of connected care solutions, including Virtual Sitter."

08:35 EST Rumble names Dr Disrespect to lead Rumble Gaming - Rumble announced that Dr Disrespect has joined Rumble and will be streaming his popular content on the platform. As part of an agreement that includes equity with milestones as a majority of its compensation, Dr Disrespect will provide exclusive content to Rumble Premium for his "Champions Club" community. Dr Disrespect will also lead Rumble Gaming, acting as an advisor and helping to build the Rumble Gaming community. Dr Disrespect's first stream on Rumble will be on December 2, 2024.

08:34 EST Verizon advances fiber network for AI workloads - AI, and specifically Generative AI with its ability for predictive analytics, is becoming a critical component of digital transformation and future business growth in almost all industries. Enterprise-grade data networks such as Verizon's (VZ) will be instrumental in these processes, and Verizon continues to advance its network components to deliver on the promises of AI. In a recent trial in Boston, Verizon moved 1.6 Tb/s of data in its live fiber network on a single-carrier wavelength using Ciena's (CIEN) WaveLogic 6 Extreme coherent optical solution. This next generation technology allows data traveling across Verizon's fiber network to travel farther and faster, leading to a better customer experience. In addition, the upgrade to this new equipment will result in higher reliability and significant energy savings in that portion of the fiber network. "AI is contingent on analyzing billions of data points in real-time on an ongoing basis. Because of the massive, multi-year transformation on Verizon's network including deploying cloud native architecture from the core to the edge, deploying massive amounts of high-performing spectrum, exponentially increasing the capacity of our fiber infrastructure and deploying advanced technologies and intelligence throughout the network, Verizon's network provides the ability to power the processes and movements of AI-generated activity," said Adam Koeppe, SVP of Technology Strategy and Planning at Verizon. "This continued advancement of our fiber network will further position us to be the provider of choice for AI workloads now and in the future."

08:32 EST Cadiz, Lytton Rancheria of California sign letter of intent - Cadiz announced that the company and the Lytton Rancheria of California have signed a Letter of Intent for Lytton to invest up to $50M in the company's groundwater banking project in the Mojave Desert. Lytton's investment would be the first major investment by a Native American Tribe in large-scale water infrastructure off tribal lands in U.S. history. With 2.5M acre-feet of new water supply and an estimated 30M acre-feet of water in storage today, the Mojave Groundwater Bank will be the largest new groundwater bank in the Southwest. The partnership between Cadiz and Lytton signifies a landmark collaboration in water resource management, with Tribes holding a majority ownership stake in the Mojave Groundwater Bank. This ownership structure empowers Indigenous communities to play a leading role in decision-making and investment in vital water projects.

08:31 EST IceCure Medical receives Notice of Allowance from Japan's Patent Office - IceCure Medical announced it has received a Notice of Allowance from the Japan Patent Office for its invention titled 'Cryogenic System with Multiple Submerged Pumps'. The patent addresses a cryogenic system featuring multiple submerged pumps that enable IceCure to introduce a groundbreaking next-generation multiprobe system. This advanced technology allows for high-end capabilities to independently control and maintain the performance of each cryoprobe, facilitating the treatment of large tumors.

08:23 EST Safe Pro subsidiary receives purchase order for drone inspection project - Safe Pro announced that its unmanned solutions subsidiary, Airborne Response, has received a purchase order for a multi-site drone inspection project to be executed in 2025 from a multinational telecommunications firm. Under the terms of the purchase order, Airborne's uncrewed aircraft systems, or UAS, teams will conduct enhanced drone-based aerial inspections and asset management services on behalf of the telecommunications customer. Airborne Response will perform aerial inspections utilizing Skydio drones to inspect multiple radio towers used by a municipal South Florida fire & rescue department.

08:19 EST Nitches, Inc. says InTheZone Labs progresses toward Amazon listing - Nitches announced strides for its flagship brand, InTheZone Labs. InTheZone Labs is in the final stages of integrating its product line with Amazon.com. The company expects the listing process to be finalized by next week, aligning inventory and systems with the website to ensure seamless fulfillment. This milestone will make InTheZone Labs' innovative bioceuticals more accessible to a wider audience, delivering the edge customers need to "Get In The Zone for 2025." InTheZone Labs has officially joined the ShareASale and Awin affiliate networks, offering partners a lucrative opportunity to promote premium, American-made supplements. Affiliates receive 20% commissions, a higher-than-average rate in the industry, with access to a growing library of promotional materials. New affiliates are encouraged to sign up and capitalize on the burgeoning demand for high-performance supplements. InTheZone Labs has been conducting rigorous Phase One testing with select groups, including U.S. veterans, former NFL athletes, a team led by a Doctor of Chiropractic, a traditional medical doctor, and other professionals. Preliminary feedback on InTheZone Focused Extreme has been positive, showcasing notable benefits: Brain Fog Reduction: Participants reported significant clarity and focus throughout the day, even in high-stress or demanding environments. Decreased Coffee Dependence: Many testers noted they no longer needed their regular coffee intake, as Focused Extreme provided sustained energy and mental sharpness. Workout Synergy: Several testers observed enhanced pre-workout focus, with effects lasting well beyond their exercise routines. One key finding from the testing revealed that larger individuals, such as former NFL players, achieved optimal results with an adjusted dosage. This feedback underscores the importance of tailoring guidance for different body types, ensuring maximum efficacy for all users.

08:18 EST Upexi files litigation over 'manipulation of fractional share roundups' - Upexi has filed a complaint in the United States District Court for the District of Nevada to pursue the groups and individuals who orchestrated the manipulative and fraudulent activity in the shares round-up scheme related to Upexi's reverse stock split. Upexi anticipates that the court, through the discovery process, will enable the Company to determine who are the individuals owning the accounts and engaged in the manipulative trading transactions within those accounts in connection with and around the announcement and effective date of Upexi's reverse stock split. The Company and its legal team will pursue aggressively obtaining the relief that it seeks in the Complaint. The Company previously announced the reverse stock split. Several weeks subsequent to the effective date, the financial institutions where the suspect trading took place requested 202,183 round-up shares, which represented more than a 19% dilution to our current shareholders and an increase of approximately 40 times the number of individual shareholders owning the Company's common stock immediately prior to the reverse split. The foregoing activity appears to have occurred during the three-day trading period between the announcement of the reverse split and its effective date. Allan Marshall, CEI, stated, "The company has taken the first and precedent-setting action in exposing the blatant manipulation around reverse stock splits. Since our previous release regarding this issue, I have been contacted by a number of companies who also were victims of this damaging stock manipulation scheme. I am astonished by the extent of the evidentiary support and encouragement I have received from multiple sources to advance our claims against those whom we believe manipulated the shares of Upexi and other securities. We believe that the evidence will identify and establish organized group trading, groups charging fees to buy and distribute shares for individuals, and individuals opening up to 50 individual accounts to perpetrate the scheme. The fact that so many microcap companies and their shareholders have been damaged in compliant reverse stock splits with no regulatory intervention to protect them against such manipulative activity is unacceptable, and we hope this lawsuit will bring into focus the need for regulatory changes to bring to an end these sinister and deceptive practices. We will follow through with this lawsuit for as long as it takes and hopefully undo some of the damage perpetrated against our shareholders by third parties and to investors in many other companies as well."

08:17 EST McCormick: Brendan Foley to succeed Lawrence Kurzius as Chairman of board - Lawrence Kurzius, Executive Chairman of the Board of McCormick & Company, announced that he will end his eight years of service as Chairman on December 31, 2024. Kurzius will continue as a Board member for McCormick, where he was employed for 22 years. He will not stand for re-election at the company's annual shareholder meeting in March 2025. Kurzius transitioned the CEO responsibilities to Brendan Foley in September 2023 and continued to serve as Executive Chairman since that time. McCormick's Board of Directors has appointed Brendan Foley, the company's President and CEO, to succeed Kurzius as Chairman, in addition to his current duties, effective January 1, 2025.

08:15 EST ARIA Cybersecurity enters reseller partnership with CED - ARIA Cybersecurity Solutions announced a new reseller partnership with CED Industrial Solutions Network a provider of Rockwell Automation sofware and equipment in the US. CED provides industrial products and solutions across 19 US states. ARIA's AZT PROTECT zero-trust solution provides a lock-down approach to protecting critical infrastructure applications from attack, with a focus on stopping all forms of malware, ransomware, as well as nation-state-backed attacks on these applications and the OS on which they run. ARIA is working with CED to resell AZT PROTECT into their customers' Rockwell Automation systems to better protect them from today's cyberattacks.

08:12 EST Vivakor completes pipeline expansion project - Vivakor has completed construction of additional gathering lines connected to its Omega Pipeline System in Blaine County, Oklahoma. Subsequent to its acquisition of the Endeavor Entities, as previously announced, in October 2024, the Company approved a project to expand its Omega Pipeline System in Blaine County, Oklahoma. The expansion is expected to result in immediate incremental customer volumes from connected oil production. The project consisted of two new gathering lines and was completed ahead of schedule and under-budget. The Omega Pipeline System is an approximately 40-mile crude oil gathering and shuttle pipeline system that serves the STACK play in Oklahoma's Anadarko Basin. It is supported by acreage dedications from key producer and marketing customers, and is connected to the Cushing, Oklahoma storage and trading hub via the Plains STACK Pipeline. The Omega Pipeline System's operations are complemented by and integrated with a fleet of approximately two dozen trucks supporting additional incremental volumes from customers.

08:10 EST iBio announces the appointment of Arkowitz, Parada to board of directors - iBio announced the appointment of biotech industry veterans David Arkowitz and Antonio Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. Arkowitz is currently Chief Financial Officer at Alkeus Pharmaceuticals, a private company developing therapies for serious diseases of the eye with high unmet need. Parada is the Founder and CEO of FairJourney Biologics, a privately held and leading antibody discovery contract research organization

08:09 EST MicroStrategy acquired 55,500 bitcoins for about $5.4B from Nov. 18-24 - In a regulatory filing, the company announced that, during the period between November 18 and November 24, the company acquired approximately 55,500 bitcoins for approximately $5.4B in cash, at an average price of approximately $97,862 per bitcoin, inclusive of fees and expenses. The bitcoin purchases were made using proceeds from the Convertible Notes Offering and the issuance and sale of shares under the Sales Agreement, both of which were previously announced. As of November 24, the company, together with its subsidiaries, held an aggregate of approximately 386,700 bitcoins, which were acquired at an aggregate purchase price of approximately $21.9B and an average purchase price of approximately $56,761 per bitcoin, inclusive of fees and expenses, MicroStrategy noted. Reference Link

08:08 EST Graphjet receives ISO certifications for graphite, graphene production - Graphjet Technology announced the Company has received ISO certifications for the manufacturing of graphite and graphene from biomass waste from ARES International, a verification services provider. The scope of the ISO certifications covered the manufacturing of biomass waste to produce artificial graphite and graphene: ISO 14001:2015; ISO 9001:2015; ISO 45001:2018.

08:06 EST Citius Pharmaceuticals reports 'constructive' FDA Type C meeting on Mino-Lok - Citius Pharmaceuticals announced that the company held a constructive in-person Type C meeting with the U.S. FDA. The meeting followed successful completion of the company's pivotal Phase 3 clinical trial of Mino-Lok, a novel catheter lock solution designed to salvage central venous catheters in patients suffering from central line-associated bloodstream infections or catheter-related bloodstream infections. The primary discussion centered on responses to the FDA's questions related to Mino-Lok's clinical trial data and a pathway to a future submission. The FDA provided clear, constructive, and actionable guidance during the discussion, underscoring a pathway to support a future New Drug Application submission for Mino-Lok. The meeting encompassed an extensive range of topics critical to the NDA process, including in-vitro, clinical efficacy and safety data, and regulatory considerations. Citius Pharma reaffirmed the potential of Mino-Lok to address a critical unmet medical need and its commitment to advancing the program. "We are highly encouraged by the collaborative and substantive nature of our engagement with the FDA regarding the Mino-Lok program," stated Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals. "The FDA's comprehensive feedback supports our commitment to advancing this novel solution for patients who face life-threatening complications from catheter-related infections. The Agency's guidance provides a strong framework for completing the remaining steps toward an NDA submission."

08:06 EST Vast receives $30M from ARENA for green technology - Vast Renewables announced it has signed an updated funding agreement to access up to $30M of its existing $65M grant from the Australian Renewable Energy Agency, ARENA. The funding will support Vast's green technology manufacturing and project development activities as it deploys its next generation concentrated solar thermal power, CSP, solution to deliver the clean, dispatchable power and heat that the world needs.

08:05 EST D-Wave Quantum up 14% premarket after AWS announces Quantum Embark program

08:04 EST Asset Entities acquired the assets of TikTok Money Machine - Asset Entities announced it has acquired the assets in the TikTok Shop space known as the TikTok Money Machine which includes its Discord community. The Discord community teaches content creators how to sell products on TikTok Shop via the use of product content videos. It also connects major consumer product brands with these content creators, offering the latter the opportunity to earn sales commissions, via their TikTok accounts, on each product sale completed. Asset Entities has also secured consulting agreements with TikTokers and lead creators of the Discord, who have an aggregate of 280,000 followers on Instagram and 4,700,000 followers on TikTok.

08:04 EST Nature's Miracle launches NM Data, invests $3M in Future Tech - Nature's Miracle announced it has formed NM Data, a Nevada Corporation and 100% subsidiary, to develop and acquire Bitcoin mining facilities. NM Data has signed an agreement to invest up to $3M in Future Tech, an Ohio-based company, to develop and build up to 50MW of Bitcoin mining and data center hosting facilities at Stryker, Ohio. With the $3M investment, NM Data will own 51% of Future Tech. The initial investment is $200,000 and the additional $2.8M is to be paid within 12 months of the initial closing. The closing of the investment of the $3M is subject to Future Tech's executing an Electricity Sales and Purchase Agreement with a certain supplier set forth in the agreement and Future Tech entering into a ten-year lease option to purchase indoor space as set forth in the agreement. NM Data will invest additional capital to complete the 50MW bitcoin mining facility.

08:03 EST Amazon's AWS announces Quantum Embark program - Amazon Web Services announced this weekend Quantum Embark, a new advisory program for customers. Quantum Embark aims to help customers get ready for quantum computing by providing an expert-led approach, as they embark on their journey, AWS said. With Embark, there are no long-term commitments, and customers can get started in as little as a few weeks, the company added. "With Amazon Braket, the quantum computing service of AWS, experienced customers can already reduce their technology risk by getting one-stop-shop access to a range of diverse quantum hardware on a pay-as-you-go basis. Now, through the new Quantum Embark program, we are adding advisory services that provide more context, guidance, and expertise to help customers who are just starting their quantum journey. This program is designed to empower customers to work backwards from their most business-critical and compute intensive use cases, develop an understanding of the state of the art, pinpoint relevant quantum technologies to focus on, and ultimately make informed decisions about future resourcing and their long-term quantum roadmap." Reference Link

08:02 EST Atlantic International secures contract with home goods distributor - Atlantic International announced its subsidiary Lyneer Staffing Solutions has been awarded a significant staffing contract with a leading international distributor of home goods. This global innovator specializes in designing and marketing a comprehensive range of household essentials, with a portfolio of well-known brands and a presence in major retailers worldwide. The partnership will initially focus on staffing flexible workforce solutions for one of the distributor's major U.S. distribution hubs, creating up to 150 new job opportunities. Based on performance, the collaboration could expand to additional locations, with total expected revenue of up to $15M annually.

07:53 EST BriaCell director Marc Lustig resigns - BriaCell Therapeutics announces that it has accepted the resignation of Mr. Marc Lustig, MSc, MBA from the Board of Directors.

07:46 EST Netlist wins $118M in second patent infringement trial against Samsung - Netlist (NLST) announced that it won a $118M damages award against Samsung Electronics, Samsung Electronics America, and Samsung Semiconductor (SSNLF) in the United States District Court for the Eastern District of Texas. The award resulted from a jury trial which involved three Netlist patents: U.S. Patent Nos. 7,619,912, 11,093,417 and 10,268,608. The infringing products were all Samsung DDR4 RDIMMs and DDR4 LRDIMMs. Netlist filed the complaint against Samsung in August 2022. The federal jury's unanimous verdict confirmed that all three Netlist patents had been infringed by Samsung, that none of the patents were invalid, that Samsung willfully infringed those patents, and that money damages were owed to Netlist for the infringement of all three patents.

07:45 EST Acreage Holdings provides update on corporate transactions - Acreage Holdings announced that, further to its press releases of June 4 and June 5, 2024, Acreage anticipates that Canopy USA will complete its acquisition of Acreage pursuant to the Acquisitions in mid-December, 2024. As further described below, as a result of the dilution in respect of the Offering completed by the Company in June 2024, the Company expects that the Exchange Ratio relating to the Fixed Shares will be significantly reduced. The reduction of the Exchange Ratio will result in fewer common shares of Canopy Growth Corporation issuable to each holder of Class E subordinate voting shares of the Company. As a result of the material impact of the Offering it is anticipated that the current holders of Fixed Shares will receive zero value upon closing of the Acquisitions. The Company expects that the Floating Share Exchange Ratio will remain as provided in the Floating Share Arrangement Agreement. Acreage is party to an arrangement agreement with Canopy dated April 18, 2019, as amended, relating to the proposed acquisition of all issued and outstanding Fixed Shares pursuant to the plan of arrangement under the Business Corporations Act. The Fixed Share Acquisition is anticipated to occur immediately after the acquisition of the Class D subordinate voting shares of Acreage pursuant to the plan of arrangement under the Business Corporations Act in accordance with the arrangement agreement dated October 24, 2022, as amended, among the Company, Canopy and Canopy USA. Upon the closing of the Acquisitions, Canopy USA will own 100% of the issued and outstanding shares of Acreage. Closing of the Acquisitions is expected to occur in mid-December, 2024, subject to the satisfaction or waiver of closing conditions, including, but not limited to, receipt by Acreage, Canopy and Canopy USA of required regulatory approvals.

07:41 EST noco-noco to appeal Nasdaq delisting determination - noco-noco announced that, on November 22, 2024 Singapore Time, it has received a determination letter from The Nasdaq Stock Market's Hearings Panel notifying the Company of its decision to delist noco-noco's securities due to non-compliance with Nasdaq's continued listing requirements. The Panel determined that the Company's securities will be suspended from trading on Nasdaq at the open of business on November 25, 2024. The Company intends to appeal the Panel's decision to the Nasdaq Listing and Hearing Review Council within the applicable 15-day appeal period. While the initiation of the appeal will not automatically stay the suspension, the Company is taking concrete measures to regain compliance with Nasdaq's listing requirements. The delisting notice will have no material impact on the Company's operations, and noco-noco will continue to focus on driving performance growth and operational efficiency.

07:40 EST Medicenna Therapeutics presents preclinical data on MDNA11 - Medicenna Therapeutics announced the presentation of preclinical data on MDNA11, a long-acting "beta-enhanced Not-alpha" IL-2 Superkine, and bizaxofusp, MDNA55, an IL-4 Empowered Superkine, at the 2024 Annual Meeting of the Society for Neuro-Oncology, SNO, held in Houston, Texas from November 21 - 24, 2024. These data provide compelling evidence of their combined potential to simultaneously enhance immune activation with MDNA11 and weaken the tumor microenvironment, TME, with bizaxofusp, for the treatment of "cold tumors" such as glioblastoma. MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells. Bizaxofusp selectively targets human tumor cells and immune-suppressive cells, enhancing anti-tumor immunity. Combination therapy with MDNA11 and Bizaxofusp demonstrates synergistic tumor-killing in human GBM tumoroids.

07:39 EST Dragonfly Energy releases Battle Born smart lithium batteries - Dragonfly Energy announces the public release of its new Battle Born smart lithium batteries, now available for purchase at special introductory pricing. This release coincides with the Company's annual Black Friday sales event, happening now through Cyber Monday, where customers can access some of the best prices of the year on all Battle Born products. The new Battle Born smart batteries feature Dragonfly IntelLigence, the Company's patent-pending technology that delivers comprehensive battery communication and monitoring capabilities. This innovation allows users to track individual battery and full battery bank performance in real-time. Through the Battle Born Mobile App, users can receive critical alerts, access detailed performance data, and review historical reports to optimize system performance. This advanced visibility enhances system configuration, streamlines troubleshooting, and ensures compliance with industry standards, including the ABYC E-13 Standards for Lithium Power Systems on Marine Vessels.

07:38 EST Anavex announces acceptance of manuscript on blarcamesine Phase IIb/III data - Anavex Life Sciences announced the acceptance of a peer-reviewed manuscript titled, "Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial," in a medical journal with focus on Alzheimer's disease. The publication date is expected around Q4 2024/Q1 2025. "The publication in a peer-reviewed medical journal is an important milestone for the Anavex team and is a testament to the importance of the findings for the scientific and Alzheimer's disease communities," said Juan Carlos Lopez-Talavera, MD, PhD, Head of Research and Development of Anavex. "We are on track for regulatory submission of oral blarcamesine in Europe in the current quarter 2024." This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.

07:36 EST Intellia announces FDA granted RMAT designation to nexiguran ziclumeran - Intellia Therapeutics (NTLA) announced that the U.S. Food and Drug Administration, FDA, has granted Regenerative Medicine Advanced Therapy, RMAT, designation to nexiguran ziclumeran for the treatment of hereditary transthyretin amyloidosis with polyneuropathy, ATTRv-PN. Development and commercialization of nex-z is led by Intellia as part of a multi-target collaboration with Regeneron (REGN). "This RMAT designation underscores the transformative potential of nex-z, our investigational in vivo CRISPR-based gene editing therapy for those living with hereditary ATTR amyloidosis with polyneuropathy," said Intellia President and Chief Executive Officer John Leonard, M.D. "It was granted following the FDA's review of our compelling interim Phase 1 data that indicated our one-time treatment led to rapid, deep and durable TTR reduction, which is expected to halt and potentially reverse the disease. We look forward to working closely with the FDA to bring this potential paradigm-shifting therapy to patients as quickly as possible."

07:35 EST SRM Entertainment secures large order from Orlando theme park - SRM Entertainment announced a significant order for its line of misting fans, designed to provide refreshing relief to theme park visitors worldwide. The initial order of $820,000 for US theme parks and $85,000 for international parks, marks a strong presence in this growing product category for SRM Entertainment.

07:33 EST Cassava announces Phase 3 ReThink-ALZ data did not meet co-primary endpoints - Cassava Sciences announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints. The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 52, assessed by the ADAS-COG12 and ADCS-ADL scales, comparing simufilam to placebo. Simufilam continued to demonstrate an overall favorable safety profile. The Company will hold a webcast at 8 AM ET. "The results are disappointing for patients and their families who are living with this disease and physicians who have been looking for novel treatment options. We took careful measures to enroll patients with mild-to-moderate AD. Despite that, the loss of cognition in the placebo group was less pronounced than was previously reported in other placebo-controlled studies in AD. We are working to understand this better," said Rick Barry, President and Chief Executive Officer. "A result like this has implications on our second Phase 3 trial, ReFocus-ALZ. We have made the difficult decision to discontinue ReFocus-ALZ, given the nature of today's reported results. The complete 52-week dataset will be available from the study along with a large portion of 76-week data. We intend to report detailed analyses of both studies in the future. We will also be discontinuing the Open Label Extension study. We have a special gratitude for the patients and their families and caregivers who participated in our clinical program for AD. We are also immensely grateful to our employees, study investigators and site coordinators, as well as our other partners, for their commitment to this program. We hope the information we have gathered can ultimately be used to benefit ongoing research in AD." Cassava will continue to review all of the data and evaluate next steps.

07:27 EST Flyht Aerospace sends management information circular for special meeting - FLYHT Aerospace Solutionshas sent, to all registered FLYHT shareholders, the management information circular and related materials for the special meeting of FLYHT shareholders to be held at 9:00 a.m. on December 16, 2024 to approve the previously announced plan of arrangement under the Canada Business Corporations Act, pursuant to which Firan Technology Group Corporation will, if the Arrangement becomes effective, acquire all of the issued and outstanding common shares of FLYHT in a cash and share transaction valued at approximately C$13.2 million, all as more particularly described in the Circular and FLYHT's news release dated October 21, 2024. FLYHT is aware that, as a result of the national strike commenced by the Canadian Union of Postal Workers on November 15, 2024, Canada Post's operations have shut down. In order to facilitate the delivery of the Circular and related materials for the Meeting to non-registered Company Shareholders in the event that the Strike, lockout or similar or related events prevent, delay or otherwise interrupt delivery of Circular and related materials for the Meeting to non-registered Company Shareholders in Canada in the ordinary course by the applicable intermediaries, FLYHT will deliver, by email, a copy of the Circular and related materials for the Meeting to each registered or non-registered Company Shareholder who requests. Non-registered Company Shareholders are also encouraged to contact the proxy department at their broker or other intermediary who can assist them with the voting process. Under the Arrangement, FLYHT shareholders may elect to receive, for each Common Share held CAD$0.1103 in cash and 0.0333 common shares of FTG, CAD$0.3379 in cash, or 0.0495 FTG Shares, in each case subject to pro-ration. The Consideration will be subject to maximum aggregate cash consideration of CAD$4.3 million and 1,300,000 FTG Shares. Shareholders who do not make an election will be deemed to have elected to receive a combination of cash and FTG Shares for their Common Shares. The Meeting is scheduled to be held virtually on December 16, 2024 at 9:00 a.m. via virtual audio teleconference call. Company Shareholders of record as of the close of business on November 6, 2024 are entitled to receive notice and vote at the Meeting. The board of directors of FLYHT, after evaluating the Arrangement with management and FLYHT's advisors, including receipt of a fairness opinion from KSV Advisory Inc., has unanimously determined the Arrangement is in the best interests of FLYHT and is fair to Company Shareholders and unanimously recommends that Company Shareholders vote FOR the Arrangement.

07:19 EST Quantum BioPharma invites shareholders to join market manipulation suit - Quantum BioPharma followed up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others engaged in market manipulation in the share price of the Company. The company said, "The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the extent determined by the courts. As a result, prominent legal teams have been assembled to pursue the recovery of all losses and damages impacting our Company. The law firms have agreed to be compensated without cost to the Company but solely on a contingency basis, meaning that the Company will not be billed for legal costs in this matter. The Company itself is seeking damages of more than $700M we believe it has suffered. The shareholders can find updated information about the case on the Quantum vs Banks page of our website which will be updated periodically. Quantum Biopharma previously know as FSD Pharma and traded under the symbol HUGE is inviting and requesting shareholders to join with the company in its quest to get justice for itself and all affected shareholders, both past and current. The company strongly believes the more affected and harmed shareholders that come forward to share specific details of their losses, the stronger the case will become against the alleged perpetrators, for the vast financial harm they have caused."

07:12 EST Macy's reports preliminary Q3 highlights - Macy's First 50 locations delivered third consecutive quarter of comparable sales growth, up 1.9%. Bloomingdale's reported comparable sales growth of owned and owned-plus-licensed-plus-marketplace up 1.0% and 3.2%, respectively. Bluemercury reported comparable sales growth of 3.3%. Asset sale gains of $66M were ahead of expectations. Preliminary Balance Sheet and Liquidity: Merchandise inventories increased 3.9% year-over-year, reflecting improved inventory composition and supply chain efficiencies. The conversion to cost accounting was estimated to account for approximately half of the increase from the prior year. Entering the fourth quarter, the company believes it has the appropriate level of newness heading into the holiday season. The company ended the third quarter of 2024 with cash and cash equivalents of $315M and $2.77B of available borrowing capacity under its asset-based credit facility reflecting current borrowings and letters of credit. Total debt of $2.865B included $86M of short-term borrowings under the company's asset-based credit facility and no material long-term debt maturities until 2027. The company voluntarily retired $220M of debt during the quarter through a previously disclosed tender offer.

07:11 EST Clearside extends global footprint with presentations at medical meetings - Clearside Biomedical announced that presentations highlighting Clearside's suprachoroidal delivery technology and data on its pipeline programs were delivered in medical meetings in Asia, Europe and the United States. Most prominently, Clearside's progress was featured in multiple activities at the 17th Asia-Pacific Vitreo-Retina Society, APVRS, Congress that took place November 22-24, 2024 in Singapore. In addition, Clearside's technology and recent ODYSSEY topline data results for CLS-AX in wet AMD were highlighted at the Ophthalmology Innovation Summit, OIS, event November 22-23, 2024 in San Diego, CA and will be presented at the upcoming FLORetina 12th International Congress on OCT and OCT Angiography in Florence, Italy being held December 5-8 2024.

07:08 EST - Mobix Labs announced it has agreed to acquire Spacecraft Component ...The acquisition, which is expected to close in the first quarter of 2025, represents a significant strategic milestone for Mobix Labs as it expands its presence into new markets and strengthens its leadership in key industries. Spacecraft Components is recognized for its cutting-edge engineering and manufacturing capabilities...As a long-standing supplier to Mobix Labs, Spacecraft Components Corp. has provided high-quality components for Mobix Labs products. This acquisition is a natural fit, allowing Mobix Labs to integrate Spacecrafts expertise and expand into the aerospace, military, and defense sectors; while also entering the transportation market as a new revenue stream. ... The acquisition is expected to increase Mobix Labs workforce by approximately 150 employees, primarily based in Nevada. Spacecraft Components reported unaudited revenues of $18.1M in 2023, with forecasted growth for the next two years. Spacecrafts compiled unaudited non-GAAP financials represent it has positive earnings and cash flow. The acquisition is expected to be accretive to Mobix Labs earnings. If the transaction closes as anticipated, it will materially increase Mobix Labs revenue in fiscal year 2025. The terms of the transaction include a purchase price ranging from $18M to $24M, with consideration to be paid in a combination of cash and equity, subject to earnout provisions, all of which will be finalized subject to completion of due diligence. The deal remains subject to final due diligence and the approval of the boards of directors of both companies.

07:08 EST Guru Organic Energy to conclude distribution agreement with PepsiCo Canada - GURU Organic Energy Corp. (GUROF) announced that its distribution agreement with The Pepsi Bottling Group, ULC, a subsidiary of PepsiCo (PEP), will conclude on May 22, 2025. The termination occurred in accordance with the terms outlined in the agreement with PepsiCo Canada signed in June 2021. GURU will transition back to its proven direct distribution model that drove GURU's growth from 1999 to 2021, ensuring uninterrupted service to retailers and consumers across Canada. Between now and May 22, 2025, GURU will work closely with PepsiCo Canada to ensure a smooth transition for all stakeholders. Post-transition, GURU plans to expand its internal sales force and reestablish partnerships with distributors who share its vision for better-for-you energy innovation.

07:07 EST U-BX Technology announces effective day for 1-for-16 reverse stock split - U-BX Technology announced that it has resolved to effect a reverse stock split of the Company's ordinary shares and has determined the ratio to be 1-for-16. At the Company's annual meeting of shareholders held on October 24, 2024, the Company's shareholders approved a reverse stock split and granted the Company's Board of Directors the authority to determine the exact split ratio and on November 2, 2024, the Company's Board of Directors determined the ratio to be 1-for-16. U-BX's ordinary shares will begin trading on an adjusted basis giving effect to the reverse stock split on November 27, 2024 under the existing ticker symbol "UBXG". The new CUSIP number of the Company's ordinary shares will be G9161K112.

07:06 EST IN8bio reports results from Phase 1 trial of INB-200 - IN8bio presented results from the fully enrolled Phase 1 trial of INB-200 in a plenary oral presentation at the 29th Annual Meeting of the Society for Neuro-Oncology in Houston, TX. The survival data along with histopathology and radiographic data are indicative of positive treatment effects, which highlight the potential of IN8bio's genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with solid tumor cancers such as glioblastoma, GBM. Key findings from the INB-200 Phase 1 trial: 92% of evaluable patients treated with INB-200 for GBM surpassed a median standard-of-care PFS of 6.9 months, with a majority exceeding their expected PFS based on their age and the MGMT status of their tumors. One patient with an IDH-mutant glioma remains alive and progression free at over 40.5 months; IDH-mutant patients in a recently published clinical trial demonstrated a median PFS of 11.1 months in the control arm and 27.7 months in the experimental arm. No treatment-related serious adverse events, dose-limiting toxicities, cytokine release syndrome, infusion reactions, or immune effector cell-associated neurotoxicity syndrome have been reported in any cohort. Gamma-delta T cells were within the normal range post-resection and remained stable with repeated doses, whereas the gamma-delta T cells in Cohort 1 continued to drop after the maintenance cycles with TMZ were initiated. This implies that repeat dosing of gamma-delta T cells may globally benefit the peripheral immune environment. T cells were low prior to surgery, rose after resection and during the cell collection for the product, were below normal during chemotherapy, and in Cohorts 2 and 3 returned to the normal range following treatment.

07:05 EST Macy's delays Q3 earnings release and conference call

07:03 EST Boston Scientific to acquire Intera Oncology, terms not disclosed - Boston Scientific announced it has entered into a definitive agreement to acquire Intera Oncology, a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine - a chemotherapy drug - both of which are approved by the U.S. FDA. The Intera 3000 pump is used to administer hepatic artery infusion therapy to treat tumors in the liver primarily caused by metastatic colorectal cancer. Boston Scientific expects to complete the transaction in the first half of 2025, subject to closing conditions. The transaction is expected to have an immaterial impact on adjusted earnings per share in 2025 and is expected to be more dilutive on a GAAP basis due to acquisition-related net charges and amortization expense. Specific terms of the transaction have not been disclosed.

06:59 EST Summit Materials to be acquired by Quikrete for $52.50 per share in cash - Summit Materials announced it has entered into a definitive agreement to be acquired by Quikrete for $52.50 per share in cash, for a total enterprise value of approximately $11.5B, including debt. The transaction price represents an approximately 36% premium to Summit's unaffected 90-day volume weighted average price and an approximately 29% premium to Summit's unaffected share price. The combination has been unanimously approved by the Summit and Quikrete boards of directors. The transaction combines Summit's aggregates, cement and ready-mix concrete businesses with Quikrete's concrete and cement-based products business to create a vertically integrated, North American, construction materials solutions provider with strong customer relationships and iconic products. The transaction is expected to close in the first half of 2025, subject to Summit shareholder approval, regulatory approvals and other customary closing conditions. Upon completion of the transaction, Summit will become a privately held subsidiary of Quikrete and its common stock will no longer be traded on the NYSE. Summit's largest shareholder, Cementos Argos, has entered into an agreement pursuant to which it has committed to vote all of its shares of Summit's common stock in favor of the transaction. Quikrete has obtained commitment letters for the financing necessary to complete the transaction, which is not subject to a financing condition. For further information regarding the terms and conditions contained in the definitive transaction agreement, please see Summit's current report on Form 8-K, which will be filed with the U.S. Securities and Exchange Commission in connection with the transaction.

06:55 EST Novartis to present data from mpre than 65 abstracts as ASH, SABCS - Novartis will present data from more than 65 abstracts, including investigator-initiated trials at the 66th American Society of Hematology, ASH, Annual Meeting & Exposition and the 2024 San Antonio Breast Cancer Symposium, SABCS. Longer-term 96-week results from Scemblix ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data. Late-breaking Kisqali 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presented. Pipeline updates demonstrate advancement in research and development programs in hematologic diseases and cancers

06:47 EST Merck reports 'positive' results from Phase 3 ZENITH trial evaluating Winrevair - Merck announced positive topline results from the Phase 3 ZENITH study evaluating Winrevair in adults with pulmonary arterial hypertension functional class III or IV at high risk of mortality. ZENITH met its primary endpoint of time to first morbidity or mortality event. In the study, Winrevair demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, both on top of background PAH therapy. Based on the strength of these results, an independent data monitoring committee has recommended ZENITH be stopped early and all participants be offered the opportunity to receive Winrevair through the SOTERIA open-label extension study. In preliminary assessment, adverse events and serious adverse events were balanced between the treatment groups.

06:34 EST EQT Corporation announces $3.5B joint venture with BXCI - EQT Corporation announced that it has entered into a definitive agreement with funds managed by Blackstone Credit & Insurance, or BXCI, to form a new midstream joint venture, or JV, consisting of EQT's ownership interest in high quality contracted infrastructure assets: Mountain Valley Pipeline, LLC - Series A, FERC regulated transmission and storage assets, and the Hammerhead Pipeline. Under the terms of the agreement BXCI will provide EQT $3.5B of cash consideration in exchange for a non-controlling common equity interest in the JV. The investment implies a total JV valuation of approximately $8.8B, or 12x EBITDA. The JV provides EQT with a large-scale equity capital solution at an accretive cost of capital. Additionally, EQT will retain the rights to growth projects associated with the assets contributed to the JV, including the planned Mountain Valley Pipeline, or MVP, expansion and the MVP Southgate project. EQT plans to use proceeds from this transaction to pay down its term loan and revolving credit facility and redeem and tender for senior notes. Pro-forma for this transaction, along with the recent announcement of the divesture of its remaining non-operated assets in northeast Pennsylvania, EQT expects to exit 2024 with approximately $9B of net debt. EQT has posted a presentation to its investor relations website with more details on the transaction. The transaction is subject to customary closing adjustments, required regulatory approvals and clearances, and is expected to close in the fourth quarter of 2024.

06:31 EST CareMax to sell core centers' assets to ClareMedica Health Partners, no terms - CareMax announced that it has entered into a "stalking horse" purchase agreement with ClareMedica Health Partners, pursuant to which ClareMedica will acquire CareMax's core centers' assets including a vast majority of CareMax's operating clinics. The transaction will be implemented pursuant to a previously announced prearranged chapter 11 plan supported and funded by 100 percent of CareMax's current secured lenders. The sale of the Core Centers' Assets is anticipated to be consummated simultaneously with CareMax's Prearranged Plan. CareMax has obtained Court approval to maintain business-as-usual operations to ensure the company's medical centers and physician affiliates continue providing uninterrupted, high-quality care and service to all patients.

06:13 EST AstraZeneca's Truqap combo demonstrated statistically significant improvement - High-level results from the CAPItello-281 Phase III trial showed that AstraZeneca's Truqap in combination with abiraterone and androgen deprivation therapy, ADT, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer, mHSPC. Overall survival, OS, data were immature at the time of this analysis; however, the Truqap combination showed an early trend towards an OS improvement versus abiraterone and ADT with placebo. The trial will continue as planned to further assess OS as a key secondary endpoint. The safety profile of Truqap in combination with abiraterone and ADT in CAPItello-281 was broadly consistent with the known profile of each medicine. Data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.

06:06 EST Old National Bancorp, Bremer Financial enter merger agreement - Old National Bancorp and Bremer Financial jointly announced today that they entered into a definitive merger agreement. Founded in 1943, BFC is the bank holding company for Bremer Bank. The Otto Bremer Trust is a private charitable trust based in St. Paul, Minnesota. It currently holds a majority ownership stake in Bremer. Upon closing of this transaction, the Trust will have an approximate 11% ownership stake in Old National and a Trustee of the Otto Bremer Trust will join the Old National Board of Directors. Under the terms of the definitive merger agreement, each outstanding share of Bremer common stock will be converted into the right to receive 4.182 shares of Old National common stock plus $26.22 in cash, valuing the transaction at approximately $1,401 million, or $116.76 per share, based on Old National's closing stock price on November 22, 2024. The definitive merger agreement has been unanimously approved by the Board of Directors of Bremer and Old National. The transaction is subject to customary closing conditions and regulatory approvals, including the approval of Bremer shareholders. The transaction is anticipated to close in the middle of 2025.

06:04 EST Durect announces sale of Alzet line of osmotic pumps to LIC for $17.5M - Durect announced the sale of its Alzet line of osmotic pumps to Lafayette Instrument, or LIC, a portfolio company of Branford Castle Partners II, a North-American focused private equity firm. Under the terms of the agreement, LIC paid Durect $17.5M in exchange for certain assets and liabilities associated with the Alzet product line. Simultaneous with this transaction, Durect has paid off all remaining obligations under the term loan agreement with Oxford Finance. Aquilo Partners acted as financial advisor and Wilson, Sonsini, Goodrich & Rosati acted as legal advisor to Durect.

05:43 EST Vertical Aerospace announces $50M in new funding - Vertical Aerospace announced the signing of a term sheet among the company, its majority shareholder Stephen Fitzpatrick, and its primary creditor Mudrick Capital Management. The VX4 during piloted, untethered testing. This term sheet secures a commitment to $50M in new funding. The funding will support the company's newly launched Flightpath 2030 Strategy that aims to establish itself as a global leader in the eVTOL market by the end of the decade, including the ongoing development and certification of the VX4.

05:34 EST Faraday Future to receive new shipment of 100 sets of Fuji vehicle body parts - Faraday Future announced it will receive a new shipment of 100 sets of Fuji vehicle body parts for FF 91 2.0 production. The company continues to work to optimize its global supplier network. The company said, "In tandem, the readiness of the first Faraday X (FX) prototype mules for shipment to the U.S. demonstrates the Company's ability to execute on multiple fronts as it advances its FX brand strategy while continuing production of the FF 91 2.0 at its FF ieFactory in Hanford, California."

05:27 EST Rocket Lab launches two missions in less than 24 hours - Rocket Lab launched its 56th Electron mission, deploying five satellites to low Earth orbit for French internet-of-things constellation operator Kineis. The "Ice AIS Baby" mission lifted-off from Rocket Lab Launch Complex 1 in Mahia, New Zealand at 4:55 pm on November 25, deploying five satellites to a 643 kilometer low Earth orbit. The mission was Rocket Lab's 14th mission of 2024 and 56th launch overall. It also brought the total count of satellites deployed by Rocket Lab to 203. The launch took place just 21 hours and 55 minutes after Rocket Lab completed a successful mission from Launch Complex 2 in Virginia, setting a new company record for fastest turnaround between launches.

05:13 EST Uxin announces change of fiscal year end - Uxin announced that the company's board of directors approved a change of the company's fiscal year end from March 31 to December 31 each year. The oompany said the primary purpose of this change is to streamline the company's financial reporting with global standards and align with industry practices, enhancing comparability with peers. This adjustment also allows the company to better synchronize operational planning and reporting cycles with market trends and customer demands. The change of fiscal year end is effective immediately.

05:05 EST Sportradar launches generative AI audio - Sportradar announced the launch of generative AI audio, a new feature within its ad:s multi-channel marketing service. The tool leverages the power of gen AI integrated with Sportradar's live data, to automate the creation of personalized, real-time audio adverts for sportsbook and casino operators across one of the fastest growing digital marketing channels globally.